Protagenic Therapeutics, Inc.\new: 10-Q filed 2020-08-14
What Protagenic Therapeutics, Inc.\new reported in its quarterly report filed 2020-08-14 (fiscal Q2 2020): 24 published measures, 68 facts as tagged in accession 0001493152-20-015885.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2020-08-14
- Fiscal period
- fiscal Q2 2020
- Accession
- 0001493152-20-015885 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Protagenic Therapeutics, Inc.\new filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | 1,187,911 | USD | |
| At 2019-12-31 | 842,273 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | 1,933,988 | USD | |
| At 2019-12-31 | 1,476,639 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | -746,077 | USD | |
| At 2020-03-31 | -585,923 | USD | |
| At 2019-12-31 | -634,366 | USD | |
| At 2019-06-30 | -379,475 | USD | |
| At 2019-03-31 | -361,820 | USD | |
| At 2018-12-31 | -210,883 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | 1,181,296 | USD | |
| At 2019-12-31 | 798,623 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-06-30 | -567,354 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -1,065,943 | USD | 182 |
| 2020-01-01 to 2020-03-31 | -498,589 | USD | 91 |
| 2019-04-01 to 2019-06-30 | -278,506 | USD | 91 |
| 2019-01-01 to 2019-06-30 | -877,738 | USD | 181 |
| 2019-01-01 to 2019-03-31 | -599,232 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-06-30 | -510,097 | USD | 182 |
| 2019-01-01 to 2019-06-30 | -276,806 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-06-30 | 900,000 | USD | 182 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-06-30 | 250,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | -16,216,144 | USD | |
| At 2019-12-31 | -15,150,201 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | 117 | USD | |
| At 2019-12-31 | 296 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-06-30 | 751,552 | USD | 182 |
| 2019-01-01 to 2019-06-30 | 711,701 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-06-30 | -488,943 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -1,009,679 | USD | 182 |
| 2019-04-01 to 2019-06-30 | -505,264 | USD | 91 |
| 2019-01-01 to 2019-06-30 | -1,159,279 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | 1,187,794 | USD | |
| At 2019-12-31 | 841,977 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | 799,900 | USD | |
| At 2019-12-31 | 1,197,269 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-06-30 | 488,943 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 1,009,679 | USD | 182 |
| 2019-04-01 to 2019-06-30 | 505,264 | USD | 91 |
| 2019-01-01 to 2019-06-30 | 1,159,279 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-06-30 | 52,008 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 117,967 | USD | 182 |
| 2019-04-01 to 2019-06-30 | 125,264 | USD | 91 |
| 2019-01-01 to 2019-06-30 | 260,675 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | 10,261,419 | shares | |
| At 2019-12-31 | 10,261,419 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | 15,642,739 | USD | |
| At 2019-12-31 | 14,687,172 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-06-30 | -173,699 | USD | |
| At 2019-12-31 | -172,364 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-06-30 | -567,354 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -1,065,943 | USD | 182 |
| 2019-04-01 to 2019-06-30 | -278,506 | USD | 91 |
| 2019-01-01 to 2019-06-30 | -877,738 | USD | 181 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-06-30 | -566,270 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -1,067,278 | USD | 182 |
| 2019-04-01 to 2019-06-30 | -278,215 | USD | 91 |
| 2019-01-01 to 2019-06-30 | -885,116 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-06-30 | 436,935 | USD | 91 |
| 2020-01-01 to 2020-06-30 | 891,712 | USD | 182 |
| 2019-04-01 to 2019-06-30 | 380,000 | USD | 91 |
| 2019-01-01 to 2019-06-30 | 898,604 | USD | 181 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-06-30 | 165 | USD | 182 |
| 2019-01-01 to 2019-06-30 | 169 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-04-01 to 2020-06-30 | -78,411 | USD | 91 |
| 2020-01-01 to 2020-06-30 | -56,264 | USD | 182 |
| 2019-04-01 to 2019-06-30 | 226,758 | USD | 91 |
| 2019-01-01 to 2019-06-30 | 281,541 | USD | 181 |
Inspect the source
- Entity
- Protagenic Therapeutics, Inc.\new / CIK 0001022899
- Captured
- 2026-09-20T05:13:45.961Z
- SEC response SHA-256
65b45c5addd26cd3e105dbeb1582537b1352dc73c447a8d926c77d81587fc033
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001022899.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))